Showing 4641-4650 of 5910 results for "".
- US Prepares for Wide Rollout of COVID-19 Boosters Next Monthhttps://modernod.com/news/us-prepares-for-wide-rollout-of-covid-19-boosters-next-month/2479458/US officials announced that health agencies in the country are preparing to widely distribute third doses of mRNA COVID-19 vaccines beginning the week of September 20, citing new data that point to waning protection over time. The move was unveiled in a statement signed by health leaders includin
- Eyeque Announces Series C Closing With More Than $57 Million in Capital Raisedhttps://modernod.com/news/eyeque-announces-series-c-closing-with-more-than-57-million-in-capital-raised/2479459/EyeQue announced that they have closed a Series C round and have raised more than $57 million in capital since the company was founded in 2015. EyeQue aims to bring affordable vision correction with their smartphone vision tests. The company has developed a suite of at-
- Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and AMDhttps://modernod.com/news/visus-therapeutics-expands-ophthalmic-drug-portfolio-with-investigational-therapies-for-glaucoma-and-amd/2479457/Visus Therapeutics announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration (AMD). The company also announced a worldwide exclusive licensing a
- Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-publication-of-positive-phase-1-clinical-data-evaluating-thr-687-for-treatment-of-dme/2479451/Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of t
- Retina Consultants of America Expands Into North Carolinahttps://modernod.com/news/retina-consultants-of-america-expands-into-north-carolina/2479446/Physician management services organization Retina Consultants of America (RCA) had added North Carolina Retina Associates (NC Retina Associates) to its national consortium. Terms of the deal were not disclosed. The addition of NC Retina Associates marks RCA’s first entry into the No
- Oculus Receives FDA Clearance for the Myopia Masterhttps://modernod.com/news/fda-clearance-for-the-new-oculus-myopia-master/2479444/Oculus announced that it has received FDA 510(k) clearance for the Myopia Master, which combines axial length, refraction values, and the central corneal radii measurements. The quick, contactless measurement method for axial length is not influenced by the accommodation status of the eye
- Sydnexis Secures $45 Million Series B Financing to Advance Myopia Drug Candidatehttps://modernod.com/news/sydnexis-secures-45-million-series-b-financing/2479442/Sydnexis announced the completion of a $45 million Series B financing to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children. The financing was led by Visionary Ventures, Blue Stem
- Visus Therapeutics to Host First Capital Markets Day in New York Cityhttps://modernod.com/news/visus-therapeutics-to-host-first-capital-markets-day-in-new-york-city/2479439/Visus Therapeutics announced that the company will host its first Capital Markets Day for investors, analysts, and media on August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue in New York City. During the Capital Markets Day, members of Visus’ leadership team and leading ey
- Oyster Point Pharma Announces License Agreement With Ji Xing Pharmaceuticals in Greater Chinahttps://modernod.com/news/oyster-point-pharma-announces-license-agreement-with-ji-xing-pharmaceuticals-in-greater-china/2479438/Oyster Point Pharma announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for the treatment of signs and symptoms of dry eye disease for patients in Greater Chi
- Rayner Announces 1,000 IOLs Recorded on RayPRO Digital Platformhttps://modernod.com/news/rayner-announces-1000-iols-recorded-on-raypro-digital-platform/2479436/Rayner announced that it has achieved the milestone figure of 1,000 intraocular lenses recorded on RayPRO, its digital patient reported outcomes platform. Launched at ASCRS in 2019 for ophthalmic surgeons who perform cataract procedures, RayPRO is a web-based and mobile digital platform th